Mats Jerkeman

• Professor
• Professor at Lund University

Background and Objectives: Mantle cell lymphoma (MCL) is a highly heterogenous disease, but an optimal prognostic biomarker in relapsed/refractory (R/R) MCL has not yet been established. The circular RNA-based risk score, circSCORE, was recently proposed as a promising prognosticator in newly diagnosed, younger patients with MCL. This study explore...

Clinical tools to guide treatment decisions in relapsed and refractory mantle cell lymphoma (R/R MCL) are limited. Moreover, the translational potential of circulating tumor DNA (ctDNA) remains largely unproven. We designed and applied panel-based duplex sequencing of ctDNA to study molecular determinants of response and outcome in 58 R/R MCL patie...

In mantle cell lymphoma, early progression of disease has been associated with short overall survival. The impact of clinical, pathological, and treatment strategies on the risk of early relapse has not been assessed in a large cohort of patients. We performed a pooled analysis of patients recruited in France from six randomized first-line MCL tria...

Relapsed or refractory mantle cell lymphoma (R/R MCL) remains difficult to treat, with outcomes dependent on the treatment regimen and remission duration after first‐line therapy. Several non‐chemotherapeutic regimens are under evaluation in R/R, but few studies report long‐term outcomes. In this study, we present the long‐term outcomes of the 50 p...

Background: The primary cause of cervical cancer is the high-risk human papillomavirus (hrHPV); the infection patterns may vary depending on the state of the vaginal immune system. Sexually transmitted infections (STIs) such as gonorrhea, trichomoniasis, and chlamydia can alter the local immune response, which in turn may affect the persistence and...

High‐risk human papillomavirus (hrHPV) genotype is needed for adequate cervical cancer screening and HPV vaccination program evaluation as recommended by different guidelines. We aimed to assess the rate of HPV infection and HPV genotype distribution using vaginal self‐sampling in a cohort of unscreened reproductive‐age women in Ethiopia. A communi...

Introduction: Sexually transmitted infections (STIs) continue to be a major public health concern and threat on a global scale. This study aimed to determine the prevalence and association of STIs coinfection with hrHPV and histological findings in a cohort of women attending cervical cancer screening with self-sampling. Method: This study was base...

There are some evidences that hypogammaglobulinemia in newly diagnosed diffuse large B cell lymphoma (DLBCL) is a predictor for inferior outcome, but the risk for infection‐related admissions specifically related to hypogammaglobulinemia is not known. The aim was to explore if hypogammaglobulinemia in untreated DLBCL in a Swedish cohort was associa...

Background One of the most detrimental late effects after treatment of lymphoma is second primary malignancies (SPM). We recently showed an increased risk of SPMs in two large population-based studies in Sweden1 and Denmark2. The aim of the current study was to investigate the impact of SPMs on survival for patients with mantle cell lymphoma (MCL)...

Introduction: The prevalence and clinical impact of clonal hematopoiesis (CH) mutations in peripheral blood (PB) of patients with aggressive large B-cell lymphomas (LBCL) has remained poorly characterized. Moreover, CH mutations partly overlap with lymphoma driver mutations, potentially compromising the specificity of emerging biomarker assays for...

Introduction Despite therapeutic advances, optimal management of mantle cell lymphoma (MCL) in young high risk patients remains an unmet need. Progression within 24 months of starting chemotherapy (POD24) indicates poor prognosis but can't guide initial therapy. TP53 mutations (Eskelund 2017) and CDKN2A deletions (del) (Delfau-Larue 2015, Le Bris 2...

Diffuse Large B-cell lymphoma (DLBCL) has a diverse response to treatment. Better understanding of the immune microenvironment may identify novel therapeutic strategies and improve stratification of patients. Lately, it has been shown that histological features not previously measured, such as distance between specific immune cells and tumor cells...

It has been established that progression of disease (POD) within 24 months in mantle cell lymphoma (MCL) patients is associated with poor prognosis. However, comparisons with progression-free (PF) patients are scarce, and the cut-off at 24 months potentially over-simplifies a more complex patient trajectory. This population-based study aimed to ass...

On behalf of the European MCL Network, ML and EH contributed equally Introduction: In younger patients with mantle cell lymphoma (MCL), the addition of ibrutinib during induction immuno-chemotherapy and as 2-years maintenance with and without autologous stem cell transplantation (ASCT) has shown high efficacy in the 3-arm randomized TRIANGLE trial...

Background: The treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has changed substantially in the last few years with the introduction of targeted and cellular therapies, mainly chimeric antigen receptor (CAR) T cell therapy. However, CAR T has been approved for use in routine care at different time points and clini...

Introduction The TRIANGLE trial (Dreyling et al. 2024) has set a novel standard in first-line treatment of mantle cell lymphoma (MCL) patients aged 18-65 years, highlighting the role of ibrutinib in the management of these patients. During the planning stage of TRIANGLE, results of the LYSA-LYMA trial showed a progression-free survival (PFS) benefi...

Introduction: Although most patients with mantle cell lymphoma (MCL) are elderly, there is no universal established standard therapy for this population. Accumulating evidence show that BTK inhibitors may have an important role in front line regimens. Ibrutinib+ rituximab was recently compared to chemoimmunotherapy in the phase 3 ENRICH trial, but...

Introduction: Current standard of care approaches for older patients with untreated mantle cell lymphoma (MCL) are rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) or Bendamustine-rituximab (BR) followed by maintenance rituximab (MR). The addition of the Bruton tyrosine kinase inhibitors (BTKis) ibrutinib and acalabrutini...

Clinical tools to guide treatment decisions in relapsed and refractory mantle cell lymphoma (R/R MCL) are limited, and the translational potential of circulating tumor DNA (ctDNA) has remained largely undemonstrated. We designed and applied panel-based duplex sequencing to uncover molecular determinants of response and outcome in the ctDNA of R/R M...

Background Most women who are high-risk human papilloma virus (hrHPV) positive in a cervical cancer screening test will spontaneously heal from their infection. Visual inspection with acetic acid (VIA) is recommended by the World Health Organization as a triage test for cervical screening, however its accuracy as a triage test has been questioned....

Background Obesity, assessed by body mass index (BMI), is an established risk factor for 13 cancers. We aimed to identify further potential obesity-related cancers and to quantify their association with BMI relative to that of established obesity-related cancers. Methods Using Cox regression models on 4,142,349 individuals in Sweden (mean age 27.1...

BACKGROUND The role of consolidation radiotherapy in primary mediastinal B-cell lymphoma (PMBCL) patients is controversial. METHODS The IELSG37 trial, a randomized non-inferiority study, aimed to assess whether irradiation can be omitted in PMBCL patients with complete metabolic response (CMR) after induction immunochemotherapy. Primary endpoint w...

Purpose Etoposide to standard R‐CHOP is used for high‐risk diffuse large B‐cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real‐world data study using matching methods was used to test the potential effectiveness of R‐CHOEP over R‐CHOP. Patients and Methods This study included patients from the Danish Lymphoma Regi...

Background and purpose: The Swedish Lymphoma Register (SLR) was initiated in the year 2000 with the aim to monitor quality of care in diagnostics, treatment and outcome of all lymphomas diagnosed nationally among adults. Here, we present the first systematic validation of SLR records as a basis for improved register quality and patient care. Patien...

Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by clinical characteristics and treatment both before and after MCL diagnosis in Sweden. Patients with a diagnosis...

Mantle cell lymphoma (MCL) is dependent on a supportive tumor immune microenvironment (TIME), where infiltration of CD163+ macrophages has a negative prognostic impact. This study explores how abundance and spatial localization of CD163+ cells are associated with the biology of the MCL TIME. This is achieved through spatial multi-omic investigation...

With the aim to advance the understanding of immune regulation in MCL and to identify targetable T-cell subsets, we set out to combine image analysis and spatial omic technology focused on both early and late differentiation stages of T cells. MCL patient tissue (n = 102) was explored using image analysis and GeoMx spatial omics profiling of 69 pro...

Highlights This EHA‐ESMO Clinical Practice Guideline provides key recommendations for managing primary DLBCL of the CNS. The guideline covers clinical, imaging and pathological diagnosis, staging and risk assessment, treatment and follow‐up. Algorithms for first‐line and salvage treatments are provided. The author group encompasses a multidisciplin...

Background The popularity of tattoos has increased dramatically over the last few decades. Tattoo ink often contains carcinogenic chemicals, e.g., primary aromatic amines, polycyclic aromatic hydrocarbons, and metals. The tattooing process invokes an immunologic response that causes translocation of tattoo ink from the injection site. Deposition of...

Patients with mantle cell lymphoma (MCL) who experience first relapse/refractoriness can be categorized into early or late progression-of-disease (POD) groups, with a threshold of 24 months from the initial MCL diagnosis. Bruton tyrosine kinase inhibitors (BTKi) are established standard treatment at first relapse, but their effectiveness as compare...

Little is known about risk factors for central nervous system (CNS) relapse in mature T- and NK-cell neoplasms (MTNKN). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at highest risk of CNS relapse. We reviewed data from 135 patie...

Background The response to immune checkpoint inhibition has been limited in mantle cell lymphoma (MCL), and the association to variation in abundance and molecular profile of different T-cell subsets is underexplored. With the aim to advance understanding of immune regulation in MCL and to identify targetable T-cell subsets in patient subgroups, we...

Epstein Barr Virus (EBV) has been recognized for its ability to transform B lymphocytes and for its association with different types of cancers including Hodgkin lymphoma. In addition, EBV may also modulate the microenvironment of HL. In this study, we aimed to investigate the prevalence of EBV among HL cases in Ethiopia and to assess the tissue ce...

Despite improvements in treatment of mantle cell lymphoma (MCL), most patients eventually relapse. In this multi-centre phase Ib-II trial, we evaluated safety and efficacy of minimal residual disease (MRD)-driven venetoclax, lenalidomide and rituximab in relapsed/refractory (R/R) MCL and explored the feasibility of stopping treatment in molecular r...

Background:Primary mediastinal B-cell lymphoma (PMBCL) is clinically and biologically distinct from other types of aggressive lymphoma, it is characterized by a bulky mediastinal mass and most commonly occurs in women between 30 and 40 years of age. Although consolidation radiotherapy (RT) has yielded extremely positive outcomes in PMBCL, it carrie...

Background: Event-free survival at 24 months (EFS24) after frontline immunochemotherapy (IC) is an important endpoint in diffuse large B-cell lymphoma and follicular lymphoma, and patients who achieve EFS24 have similar survival compared to age- and sex-matched general population. The role of EFS24 in predicting subsequent survival has not been est...

Introduction HPV vaginal self-sampling is more acceptable by women than health-provider cervical cancer screening methods. However, only a minority of HPV positive women will need treatment for pre-cancerous lesions, which requires an effective triage test. Visual inspection with acetic acid (VIA) is recommended as a triage, but the sensitivity and...

Background Deciphering the tumor-immune microenvironment (TIME) and the impact of cell-to-cell interaction for immunotherapy response is pivotal for developing biomarker signatures for patient stratification and novel therapies. Spatial phenotyping and functional deconvolution of the TIME can be achieved by using spatial omics technologies. Further...

The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell th...

The transcription factor MYC is a well-described oncogene with an important role in lymphomagenesis, but its significance for clinical outcome in mantle cell lymphoma (MCL) remains to be determined. Here, we perform an investigation of the protein expression of MYC in a cohort of 251 MCL patients complemented with analyses of structural aberrations...

Epstein Barr Virus (EBV) has been recognized for its ability to transform B lymphocytes and for its association with different types of cancers including Hodgkin lymphoma. In addition, EBV may also modulate the microenvironment of HL. In this study, we aimed to investigate the prevalence of EBV among HL cases in Ethiopia and to assess the tissue ce...

Mantle cell lymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Here, we present a nationwide assessment of treatment strategies, time to progression and survival in MCL. All patients diagnosed with MCL 20...

Currently, treatment allocation of patients with Mantle Cell Lymphoma (MCL) is mainly based on age and medical fitness. The combined MCL International Prognostic Index (MIPI-c) allows to predict prognosis using clinical factors (MIPI) and the Ki-67 index. However, high p53 expression as surrogate for TP53 alterations has demonstrated to be an indep...

The outcome for patients with mantle cell lymphoma (MCL) has drastically improved with new treatments directed towards the tumor immune microenvironment, where macrophages play an important role. In MCL, the presence of M2 macrophages defined by CD163 expression in diagnostic biopsies has been associated with a worse prognosis. An alternative way t...

Background Cervical cancer is a major global health issue, with 89% of cases occurring in low- and middle-income countries (LMICs). Human papillomavirus (HPV) self-sampling tests have been suggested as an innovative way to improve cervical cancer screening uptake and reduce the burden of disease. The objective of this review was to examine the effe...

LBA7505 Background: Primary mediastinal B-cell lymphoma (PMBCL) has a good prognosis if remission is rapidly achieved with dose‐intensive immunochemotherapy. In these patients mediastinal radiotherapy (RT) may consolidate responses; however, it increases the risk of second malignancies and coronary or valvular heart disease. The IELSG37 trial was p...

There are some evidences that hypogammaglobulinemia in newly diagnosed diffuse large B cell lymphoma (DLBCL) is a predictor for inferior outcome, but the risk for infection-related admissions specifically related to hypogammaglobulinemia is not known. The aim was to explore if hypogammaglobulinemia in untreated DLBCL in a Swedish cohort was associa...

Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease, emphasizing the need for prognostic biomarkers. In this study we aimed at comparing the prognostic value of two RNA-based risk scores, circSCORE and MCL35, in 149 patients from the MCL2 (ISRCTN87866680) and MCL3 (NCT00514475) patient cohorts. Both risk scores provide...

Currently, treatment allocation of patients with Mantle Cell Lymphoma (MCL) is mainly based on age and medical fitness. The combined MCL International Prognostic Index (MIPI-c) allows to predict prognosis using clinical factors (MIPI) and the Ki-67 index. However, high p53 expression as surrogate for TP53 alterations has demonstrated to be an indep...

Peripheral T‐Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited‐stage disease is infrequent and not well‐described. This study reports outcomes and prognostic factors in limited‐stage nodal PTCLs in a binational population‐based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adu...

The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL international prognostic index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative tre...

Background: CD70 is a costimulatory molecule that is transiently expressed on a small set of activated lymphocytes and is involved in T-cell-mediated immunity. However, the role of CD70 in B-cell malignancies remains controversial. Methods: We investigated the clinical relevance of CD70 genetic alterations and its protein expression in two diffu...

Central nervous system (CNS) relapse (CNSr) in patients with aggressive non-Hodgkin lymphoma is uncommon but carries a high morbidity and mortality. Data in T- and NK-cell lymphomas (TCL) are sparse, though the few small case series describing CNSr in TCL report an incidence up to 9% with median overall survival (mOS) less than 3 months (mo). We pr...